Mirum jumps after brelovitug hits Phase 2b AZURE-1 primary endpoint in hepatitis delta
Mirum Pharmaceuticals (MIRM) is rising after disclosing new Phase 2b AZURE-1 data showing its hepatitis delta candidate brelovitug met the primary endpoint at Week 24. The company reported 45% and 35% primary composite response rates in two dosing arms versus 0% in a delayed-treatment arm.
1. What’s moving the stock today
Mirum Pharmaceuticals shares are moving higher on April 27, 2026 after the company filed an 8-K announcing that the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an investigational monoclonal antibody designed to bind hepatitis B surface antigen (HBsAg), for chronic hepatitis delta virus (HDV). (sec.gov)
2. The key data investors are reacting to
The Phase 2b portion included the first 53 patients evaluated at Week 24. Mirum reported virologic response rates of 100% (300 mg once weekly) and 75% (900 mg once every four weeks) versus 0% in the delayed-treatment arm, and said the primary composite endpoint (virologic response plus ALT normalization) was achieved in 45% and 35% of patients in the two active-treatment arms versus 0% in the delayed-treatment arm. (sec.gov)
3. What’s next and why it matters
Mirum said the full Phase 2b results will be presented as a late-breaking poster at the European Association for the Study of the Liver (EASL) Congress on May 27–30, 2026. The company also guided that topline data from the Phase 3 AZURE-1 and AZURE-4 studies are expected in the second half of 2026, with potential BLA submission and a U.S. commercial launch in 2027—timelines that help frame today’s move as investors reprice the probability of late-stage success. (sec.gov)